# Cathie Wood

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/cathie-wood
Canonical HTML page: https://getbiobrief.com/entity/cathie-wood

## Recent coverage (2 stories)

### ARK Invest Doubles Down on Tempus AI Amid Precision Medicine Volatility
2026-03-16 00:32:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Cathie Wood's ARK Investment Management has purchased $2 million worth of Tempus AI shares, reinforcing its position in the precision medicine firm despite a 15% year-to-date decline. The move underscores Wood's commitment to 'coiled spring' AI and biotech assets, even as her flagship funds face significant performance headwinds compared to the broader market.
Full story: https://getbiobrief.com/story/ark-invest-tempus-ai-purchase-precision-medicine

### Cathie Wood’s ARK Invest Doubles Down on CRISPR Therapeutics Amid Market Dip
2026-03-11 11:48:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
Full story: https://getbiobrief.com/story/cathie-wood-ark-invest-crispr-therapeutics-buy-dip

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.